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Abstract  
 
Uterine artery embolisation (UAE) is a recognised alternative to surgery for treatment of uterine 
fibroids and maintains fertility for the majority of women.  Premature ovarian failure (POF) can 
occur in a small proportion of women undergoing UAE (1-3%).  Identification of prognostic 
factors for POF following UAE would allow accurate and informed counselling for those 
patients wishing to retain fertility and avoid a premature menopause.  The aim of this study was 
to evaluate and compare ovarian functional outcomes following surgical treatment 
(hysterectomy or myomectomy) and UAE. 
 
The randomised trial of embolisation versus surgery (REST) recruited 157 patients (UAE 106, 
51 surgery).  Of these patients, 96 (73 UAE, 23 surgery with retained ovaries) had serum FSH 
and LH measurements taken on day 3 of the menstrual cycle prior to treatment and at 6 and 12 
months post-treatment.  Data on menstrual cycle characteristics were also collected.  
 
The median increase in FSH levels (from baseline to 12 months) was 1.7 IU/L (p = 0.01) 
following UAE and 2.4 IU/L (p = 0.09) after surgery.  There was no significant difference in the 
median change in FSH at 12 months between UAE and surgical patients (p=0.54).  In patients 
aged >45 years, the surgical group had a higher median increase in FSH level compared to the 
UAE group (34 v 4 IU/L; p = 0.01) from baseline to one year post treatment.  UAE patients had 
a decrease of 1.4 days (95% CI 0.6 to 2.2; P=0.001) in the mean duration of menstrual flow from 
baseline (mean 7; SD 3) to six months post- embolisation.   However, there was no change (-0.2 
days; 95%CI -1.1 to 0.6; p=0.56) in the mean cycle length from baseline values (mean 27.4; SD 
2.8).  Ovarian failure (FSH > 40 IU/L up to 2 years after treatment) did not occur in either 
treatment arm in women under 40 years of age.  
 
UAE and surgery both cause a small change in ovarian function at 1 year with no significant 
difference between the two groups.  Patients over the age of 45 years are at much greater risk.   
Changes in ovarian function are not reflected in the length of the menstrual cycle following 
UAE. 
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Introduction 
 
Uterine fibroids are common benign tumours which occur in 20-30% of women during 
reproductive life, rising to 40% in women above the age of fifty years who are still 
menstruating1.  Although the majority of cases are asymptomatic, fibroids can grow to a 
considerable size, causing problems such as menorrhagia, dysmenorrhoea, pelvic pressure 
symptoms and infertility1.  Up until recently, the standard surgical treatment for fibroids was 
either hysterectomy or myomectomy.  The latter has been the principal option for those wishing 
to retain their fertility however myomectomy can be associated with pre and post-operative 
complications such as adhesion formation which may further decrease reproductive capacity.  In 
1995 Ravina introduced uterine artery embolisation (UAE), an alternative non-surgical 
technique for the treatment of fibroids.  This procedure significantly decreases fibroid related 
symptoms2 and is also used to control post-partum haemorrhage and post surgical bleeding3. 
 
Numerous studies, including randomised controlled trials have demonstrated the safety and 
efficacy of UAE.  It is associated with low morbidity rates4 and complication rates are similar to 
or less than those associated with surgery5,6.  In addition, compared with surgical treatment, 
UAE necessitates a significantly shorter hospital stay and faster recovery of lifestyle milestones6-
9.  Other benefits include a decrease of up to 50% in fibroid diameter10,11 with larger reductions 
in uterine volume12  and a significant decrease in fibroid related symptoms10, 13-17.  Emerging 
midterm data estimates new fibroids occur in up to 10% of cases at 2 years after UAE18, which is 
significantly lower than those reported after myomectomy19.  Longer term data are just emerging 
but current data suggest that 15-25% require further invasive treatment (repeat UAE, 
hysterectomy or myomectomy) at 5 years for recurrent symptoms.  Nevertheless, several 
complications associated with UAE have also been reported4, 14, 17, 20-23 including pelvic 
infection,  premature ovarian failure (POF) and emergency hysterectomy, all of which severely 
compromise fertility.   
 
The impact of UAE on subsequent fertility and menstrual cyclicity is not well-characterised. 
POF is an undesirable complication of UAE for fibroids, although its occurrence is unusual 
when embolisation is performed in other circumstances e.g. post partum haemorrhage24.  Despite 
the fact that resumption of normal menses has been reported in most women, numerous reports 
of amenorrhoea post UAE (both transient and permanent) have been documented throughout the 
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literature.  Amenorrhoea rates vary from 1-2%2, 12, 6-8%13, 14, 16   and even 14%26.  It appears that 
the incidence of POF may be age dependent since as many as 43% of woman above the age of 
45 years become amennorhoeic after the procedure26,27.  Thus POF seems to be uncommon in 
those who are most likely to wish to conceive. 
 
During the menopausal transition, changes in the menstrual cycle are also observed reflecting the 
changes in gonadotrophin levels and output of ovarian steroids28.  Thus it is important to 
examine the effect of UAE on menstrual cyclicity and duration of menstrual flow. 
 
The purpose of this study is to investigate whether UAE causes a change in ovarian function (as 
assessed by gonadotrophin levels) which differs from that induced by surgical treatment in 
woman with uterine fibroids.  The impact of age on ovarian function, and whether or not any 
changes in ovarian function are reflected by an alteration inwhether any changes in ovarian 
function are reflected in an alteration in menstrual cyclicitycharacteristics, are also reported. 
 
Material and Methods 
Patients 
The data for this study was taken from a multicentre randomised controlled trial comparing 
uterine artery embolisation with surgical treatment (REST trial)6 for uterine fibroids.  This trial 
recruited 157 patients, 106 of whom were randomised to embolisation and 51 to surgery, 
predominately hysterectomy, using a 2:1 randomisation and stratification for centre.  Multi 
centre ethical approval was granted and local ethics approval was obtained by each participating 
centre.  Each patient gave consent to the gathering of follow up data.  Full details of this study 
have already been reported6. 
 
Procedures 
Uterine artery embolisation (UAE) was performed using a variety of embolic agents.  The 
preferred endpoint of embolisation was complete or near complete stasis of the uterine artery. 
The precise surgical technique (hysterectomy or myomectomy) was left to the individual 
operator.  Post-procedural and follow-up protocol including clinical and quality of life outcomes 
have been reported elsewhere6. 
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Study Design and Data Collection 
For the purpose of the hormone study and to allow a comparison of gonadotrophin levels 
between women undergoing UAE and surgery, only patients with ovarian conservation at the 
time of surgery were included.  Those already menopausal at the time of treatment, with 
measured FSH levels of 40 IU/l or greater in the early follicular phase of the cycle, were 
excluded from the study as were patients taking exogenous hormones at the time of pre- and 
post-treatment blood sampling.  Data analysis was carried out on a final cohort of 96 patients (73 
UAE and 23 surgical). 
 
Baseline blood biochemistry results including follicle stimulating hormone (FSH) and lutenising 
hormone (LH) were obtained within 7 days of onset of menses, primarily on day 3 of the 
menstrual cycle.  These measurements were made prior to treatment and repeated at 6 and 12 
months after treatment.  Hormone assays were performed with commercially available 
immunoassay kits.  Basal FSH and LH levels were recorded in all patients.  At the 6 month 
interval, serum FSH and LH results were available for 66 of 73 (90%) UAE patients and 22 of 
23 (96%) surgical patients.  At the 12 month interval, serum FSH results were available for 62 
(85%) UAE patients and 17 (74%) surgical patients.  LH results were available for 61 (84%) 
UAE patients and 16 (70%)  surgical patients.  
Patients’ menstrual cycle data were collected from those women who underwent UAE and  
myomectomy.  This included the duration of bleeding and the length of the menstrual cycle. 
Data were obtained from forms completed by hospital research nurses prior to the patients’ 
treatment and at 6 and 12 month reviews.  Patients’ menstrual diaries were used to clarify the 
data.  Bleeding data were available for 101 patients but 23 patients were excluded, leaving a 
cohort of 78 patients.  Reasons for exclusion included missing data, irregular bleeding, 
continuous bleeding prior to treatment, amenorrhoea due to the menopause, the use of 
exogenous hormones and hysterectomy.  Of the 78 cases, only 2 had myomectomy thus it was 
decided to report the menstrual cycle data only for the 76 UAE cases.  Baseline menstrual data 
were available for all 76 patients.  At the 6 month follow-up, data on the duration of bleeding 
and the length of the menstrual cycle were available for 75 (99%) patients and 73 (96%) 
patients, respectively.  At the 12 months post-UAE, the corresponding figures were 69 (91%) 
patients and 66 (87%), respectively. 
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Study Aims 
The primary aim of the study was to determine if there was any difference in ovarian function 
post-treatment (as reflected by gonadotrophin levels) between those undergoing UAE and 
surgery, and to determine if the age of the patient influenced any effect that UAE might have on 
ovarian function.  A secondary aim was to determine if UAE had an effect on the duration of 
menstrual flow and the length of the menstrual cycle.  
 
Statistical Analysis 
Changes in gonadotrophin levels (baseline to post-treatment) in each treatment group were 
analysed using the Wilcoxon Signed rank test.  Comparisons of the change in hormone levels 
between groups were carried out using the Mann-Whitney test.  For the menstrual cycle 
characteristics (duration of bleeding and length of menstrual cycle), paired t-tests and 95% 
confidence intervals were used to examine the differences between baseline and post-treatment 
values.  A p-value of <0.05 was considered statistically significant.  All analyses were carried 
out using the statistical software package Minitab, versions 15. 
 
Results 
 
Hormone Study 
 
The final patient cohort for the hormone study consisted of 96 patients (73 UAE and 23 surgery). 
The hormone levels of the patients are summarised in Table 1.  Both treatment groups were 
well-matched for age.  The mean (SD) age of the patients was 43.8 (5.4) years in the UAE group 
and 42.5 (5.2) years in the surgery group.   
 
The effect of treatment on gonadotrophin levels 
The change in FSH and LH levels from baseline to 6 and to 12 months after treatment are shown 
in Table 2.  There were significant increases in FSH and LH levels at both 6 months and 12 
months for the UAE patients.  Although the increases in levels in the surgical patients were 
generally of a similar or greater magnitude, the smaller sample size meant that the increases 
were not statistically significant.   
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UAE versus Surgery 
There was no significant difference in the median change in either hormone level at 6 and 12 
months between the UAE and surgery groups (Table 2). 
 
The impact of age 
Women aged 45 years and over showed a larger median increase in both FSH and LH at both 6 
months and 12 months after treatment compared to women under the age of 45 years (Table 3) 
although this difference was only statistically significant at 12 months.   
            
Table 4 shows change in FSH / LH levels as in Table 2 splitting the group into age ≥45 years 
and < 45 years.  In women <45 years there were no statistically significant changes in hormone 
level.  In women ≥45 years there were statistically significant increases in FSH levels at 1 year 
in both the UAE and surgery groups.  In a comparison of UAE and surgery in women under 45 
years there were no statistically significant differences between UAE and surgery in the median 
change in hormone levels after treatment.  In women ≥45 years the surgical cases had a 
significantly greater increase in FSH level at 1 year compared with UAE; no other comparisons 
were statistically significant 
 
Ovarian Failure after Treatment  
Ovarian failure after treatment, defined as an FSH in excess of 40IU/l, developed in a total of 16 
patients ((13 UAE and 3 surgery (2 myomectomy, 1 hysterectomy)) of whom 14 were aged ≥ 45 
years.  Both younger patients (43 and 44 years; received UAE) and 4 of the patients aged ≥ 45 
years (all underwent UAE) had an elevated basal FSH at the time of treatment (>19 IU/l) 
indicating their peri-menopausal status.  Follow-up review indicated that all 15 patients (16th 
patient underwent hysterectomy) had menstrual bleeding in the year following treatment. 
 
 
 
Menstrual Cycle Study 
 
The menstrual cycle length and menstrual flow data are summarised in Table 1. 
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The effect of UAE on menstrual cycle characteristics  
The effect of treatment on menstrual cycle is shown in Table 5.  The mean duration of menstrual 
flow, assessed by the number of days bleeding, decreased significantly from baseline to 6 and 12 
months by 1.4 days (SD 3.7) and 1.7 days (SD 3.8), respectively.  There was no statistically 
significant change in the mean cycle length at both 6 months (-0.3days (SD 3.8)) and 12 months 
(0.7days (SD 4.9)).  
 
 
Discussion 
 
The issue of possible ovarian dysfunction as a consequence of UAE has been raised following 
reports of amenorrhoea and increased FSH levels (within the menopausal range) post-
treatment20, 26, 27, suggesting ovarian failure as a cause of amenorrhoea. 
 
Data from the EMMY study confirm that there is an increase in FSH levels associated with a 
decrease in ovarian reserve following both surgical treatment and UAE, although it is unclear to 
what extent increasing age as opposed to the procedures themselves, contribute to this27.  It 
should be noted that the majority of those in the EMMY study were over 40 years of age and 
antimullerian hormone (AMH) which was used to assess ovarian reserve, becomes undetectable 
in most women at that age.  Consequently, changes in AMH could not be detected and 
conclusions regarding diminished ovarian reserve therefore, cannot be drawn.  Since all the 
women in the surgical arm of that study had hysterectomy, the impact of treatment on bleeding 
pattern could not be determined as it can be following myomectomy.  These reports have raised 
concerns about the potential impact of UAE on reproductive function, an aspect of treatment 
which is particularly important for those wishing to conceive.  Bearing this in mind, some 
authors suggest that reproductive function should be assessed using gonadotrophin 
measurements prior to the procedure14, 26.  
 
To assess the effect of UAE and surgery on ovarian function, basal gonadotrophin values 
obtained in the early follicular phase of the menstrual cycle were used as indicators of ovarian 
function29.  In our study, UAE patients had a statistically significant increase in median FSH and 
LH values post-treatment compared with baseline values.  These findings correlate with previous 
reports30 and suggest that UAE has an adverse effect on ovarian function.  Surgical patients also 
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had higher median FSH and LH levels post-treatment but the increase from baseline levels, 
although of a similar magnitude, was not statistically significant.  The surgical group was small 
and the gonadotrophin levels highly variable in spite of all the samples being collected in the 
early follicular phase of the cycle.  Although our study was underpowered, the data suggest that 
the impact of surgery on hormone levels is similar to that of UAE.  There was no significant 
difference in median change in gonadotrophin levels at 6 and 12 months post-treatment between 
UAE and surgical patients 
 
Age had a significant impact on the results.  Both UAE and surgical patients ≥45 years had 
significantly higher median levels of FSH and LH at 12 months post-treatment compared to 
baseline whilst women < 45 years of age did not.  Previous studies have reported an age-related 
susceptibility to menopause post-UAE16, 26, 31.  Spies et al31 also reported that woman over the 
age of 45 have a 15% chance of an increase in basal FSH levels into the menopausal range after 
UAE.  Although patients in our study over the age of 45 demonstrated statistically significant 
increases in gonadotrophin levels, the median FSH values at 6 and 12 months post-UAE were 
10.2 IU/l and 14.0 IU/l, respectively - values that were still in the pre-menopausal range 1 year 
after treatment.  Surgical patients over 45 years of age had a higher median increase in FSH 
value at 12 months post-treatment than UAE patients of the same age category (the median FSH 
value in the surgical group of women ≥45 years of age was 37.5 IU/l at 12 months, which is 
within the menopausal range).  This was despite the fact that all surgical patients reported in this 
paper had conservation of their ovaries. 
Studies which have examined the effect of surgery on ovarian function have reported similar 
observations.  Beavis et al32 studied a group of pre-menopausal patients who underwent total 
abdominal hysterectomy with ovarian conservation and found a rate of hysterectomy-induced 
ovarian failure of 15% which is very similar to that reported with UAE by both Chrisman26 and  
Siddle et al33.  This study and others34 have emphasised the importance of the role of a viable 
uterus, or an intact blood supply, on normal ovarian function.  Several mechanisms have been 
proposed in an attempt to explain the apparent change in ovarian function after UAE. 
Anastomoses between uterine and ovarian vessels have been described in up to 10% of women 
undergoing UAE35.  Subsequently, there have been reports of non-target embolisation with 
embolic particles in the ovarian circulation, causing a decrease in the blood supply to the 
ovaries36.  The increased risk of ovarian dysfunction in older women undergoing UAE could be 
due to the fact that older women are more sensitive to disruptions in vascular supply.  It could 
also be postulated that an increase in gonadotrophins in women over the age of 45 is the result of 
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natural ageing.  No surgical patients were classified as postmenopausal (FSH > 40 IU/L level) 
prior to treatment. Less than 10% of women in the UAE arm were postmenopausal pre-
embolisation, most of whom were aged > 45 years.  At follow up, both surgical and UAE 
patients had a statistically significant increase in median gonadotrophin levels from pre- to post-
treatment.  When examining the effect of age on gonadotrophin levels in this study, it may have 
been of greater value to compare patients over and under 40 years of age since FSH levels start 
rising  around  the age of 37 years28 and fertility is usually less of an issue for women over 40 
years.  However, this was not possible due to the small number of patients under 40 years of age 
in both treatment groups.  Despite the fact that there have been reports of POF post-UAE in 
younger woman10, 37, no women in our study under the age of 40 years became menopausal 
during the 1 year follow up period.  In addition, there was little deviation from baseline values of 
gonadotrophins in women < 45 years of age after treatment.  Thus, in our study population,  
UAE does not have an effect on ovarian function in younger women.  
 
 A significant decrease in the mean duration of menstrual flow from pre- to post-treatment has 
also been reported in other studies16, 38.  This is of clinical benefit to women undergoing UAE for 
fibroids as the majority present with heavy menses and an increased duration of menstrual 
bleeding.  In contrast, there was no statistically significant difference in the mean cycle length 
before and after UAE.  This is rather surprising and suggests that the changes in gonadotrophins 
induced by UAE were not reflected by changes in the menstrual cycle.  
 
In conclusion, this study has shown that both UAE and surgery  cause a statistically significant 
change in ovarian function post-treatment  as assessed by gonadotrophin levels in women over 
45 years of age.  It has also demonstrated that there is no significant difference in the increase in 
post-treatment gonadotrophin levels between patients undergoing UAE compared to surgery. 
Our results in women under the age of 45 years were reassuring and suggest that ovarian 
function may be preserved in such women after UAE.  In addition, UAE offers symptomatic 
relief by causing a statistically significant decrease in the mean duration of menstrual flow. 
Whilst there is a statistically significant increase in gonadotrophin levels post UAE, this does not 
appear to have a clinically significant effect. 
 
Further studies, with age-controlled comparisons between UAE and surgery, need to be carried 
out in larger patient cohorts to determine the likelihood of premature ovarian failure in women 
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undergoing UAE.  In particular, the real possibility of iatrogenic ovarian failure after UAE 
merits careful consideration in patients desiring future fertility. 
 
 
 
Conclusions 
1. Both UAE and surgery lead to small increases in gonadotrophin levels.  
2. The increase in gonadotrophin levels is only significant in women over the age of 45 
years. 
3. Impaired ovarian function it is not reflected in an alteration in the length of the menstrual 
cycle although the length of the menses is shortened. 
4. All women, particularly those in their 40s who desire future fertility, must be very 
carefully counselled regarding ovarian failure, prior to UAE. 
5. The impact of myomectomy on ovarian function requires a larger study. 
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Table 1.   Hormone levels (n = 96) and menstrual cycle characteristics (n = 76) of women at 
baseline and at 6 and 12 months post-treatment. 
 
 
 
Hormone Levels (n = 96) 
 
UAE ( n = 73) 
 
Surgery (n = 23) 
 
 
 
 
 
Baseline 
6 months 
12 months 
FSH (IU/L) 
 Median; range, 
(interquartile range) 
 
6.7; 0.8 – 38.7, (4.4 – 11.3) 
7.5; 0.6 – 112, (4.3 – 16.0) 
7.8; 1.7 – 120, (5.4 – 14.7) 
FSH (IU/L) 
 Median; range, 
(interquartile range) 
 
6.2; 2.2 – 14.7, ( 4.2 – 8.3) 
8.9; 0.5 – 28.1, (4.2 – 12.2) 
7.6; 4.3 – 81.0, (5.4 – 24.8) 
 
 
 
Baseline 
6 months 
12 months 
LH (IU/L) 
Median; range, 
(interquartile range) 
 
5.6; 0.5 – 45.8, (3.5 – 8.2) 
6.8; 1.4 – 103, (4.0 – 22.1) 
6.1; 2.1 – 60.8, (4.3 – 13.5) 
LH (IU/L)  
Median; range, 
(interquartile range) 
 
4.2; 1.4 – 12.1, (2.9 – 6.3) 
4.8; 0.5 – 56.4, (3.0 – 10.6) 
7.9; 0.5 – 56.2, (13.4 – 19.1) 
 
 
Menstrual cycle (n = 76) – UAE patients only                
 
Menstrual flow duration  
Baseline 
6 months 
12 months 
 
Mean (SD) - days 
7.1 ( 3.3) 
5.7 (2.7) 
5.6 (2.8) 
 
Length of menstrual cycle  
Baseline 
6 months 
12 months 
 
 
Mean (SD) - days 
27.4 (2.8) 
27.2 (3.3) 
28.0 (4.3) 
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Table 2.    Change in FSH and LH levels from baseline to 6 and 12 months after treatment for 
UAE and surgery and a comparison between UAE and surgery 
 
 
 
 UAE ( n = 73) Surgery (n = 23) Difference  
UAE – Surgery 
 
 
Change in FSH (IU/L) 
median; IQR  
(p-value for increase) 
median; IQR  
(p-value for increase) 
p – value  
( 95% CI for median 
difference) 
Increase at 6 months 1.1;  -2.3 to 9.1    
(p = 0.04) 
1.0; -2.7 to 6.2      
(p = 0.18)  
0.81 
(-3.2 to 3.6)  
Increase at 12 months 1.7; -2.6 to 8.1       
(p = 0.01) 
2.4; -2.3 to 19.4       
(p = 0.09) 
0.54 
(-8.7 to 3.7) 
    
 
Change in LH (IU/L)  
   
Increase at 6 months 2.0; -0.8 to 12.8       
(p = 0.001) 
0.8; -2.1 to 4.5       
(p = 0.30) 
0.36 
(-1.5 to 4.1) 
Increase at 12months 1.5; -1.5 to 6.5       
(p = 0.01) 
2.4; -1.0 to 14.4       
(p = 0.07) 
0.50 
(-7.1 to 2.2) 
IQR – inter-quartile range  
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Table 3.     Change in FSH and LH levels from baseline to 6 and 12 months after treatment in 
women ≥ 45 years compared to those < 45 years of age. 
 
 
 
 ≥45 years  
n =48  
< 45 years 
n =48 
Difference 
(≥45 years  – <45 years)  
 
Change in FSH 
(IU/L) 
 
median; IQR 
 
median; IQR 
 
p – value 
(95%CI for median difference) 
Increase at 6 months 
 
2.1; -3.2 to 21.7 0.8; -2.3 to 3.6 0.33 
(-1.7 – 5.5) 
Increase at 12 months 
 
6.8; -2.6 to 21.8 0.3; -2.4 to 4.2 0.01 
(1.3 – 12.5) 
    
 
Change in LH (IU/L)  
   
Increase at 6 months 
 
1.8; -0.6 to 20.5 1.4; -2.3 to 3.6 0.28 
(-1.0 – 5.5) 
Increase at 12months 
 
2.2; 0.6 to 13.8 0.2; -2.1 to 3.9 0.04 
(0.2 – 6.7) 
IQR – inter-quartile range  
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Table 4.   Change in FSH and LH levels from baseline to 6 and 12 months after treatment for 
UAE and surgery and a comparison between UAE and surgery  for women  ≥ 45 years and for 
those < 45 years of age. 
 
 
 
 UAE  Surgery  Difference 
UAE - Surgery 
 
45 years and over n = 41 n = 7  
 
Change in FSH (IU/L) 
 
median; IQR 
(p-value for increase) 
 
median; IQR 
(p-value for increase) 
p-value (95%CI 
for median 
difference) 
Increase at 6 months 1.1; -3.6 to 28.9 
(0.12) 
4.6; 1.1 to 10.0 
(0.05) 
0.43 
(-15.1 to 11.2) 
Increase at 12 months 4.4; -3.2 to 18.2 
(0.03) 
33.7; 3.5 to 58.9 
(0.04) 
0.01 
(6.9 to 51.3) 
    
Change in LH (IU/L)     
Increase at 6 months 1.9; -0.3 to 22.1 
(0.01) 
0.8; -1.5 to 4.0 
(0.45) 
0.38 
(-20.6 to 2.5) 
Increase at 12months 2.0; 0.3 to 10.2 
(0.01) 
14.9; 6.9 to 32.4 
(0.06) 
0.06 
(-0.1 to 26.6) 
    
Under 45 years n = 32 n = 16 p-value (95% 
CI for median 
difference) 
Change in FSH (IU/L) median; IQR 
(p-value for increase) 
median; IQR 
(p-value for increase) 
 
Increase at 6 months 1.0; -1.0 to 4.0 
(0.09) 
-0.8; -2.7 to 3.2 
(1.0) 
0.21 
(-4.4 to 1.3) 
Increase at 12 months 0.7; -2.0 to 4.8 
(0.18) 
-0.7; -3.0 to 2.4 
(0.56) 
0.27 
(-5.4 to 1.5) 
    
Change in LH (IU/L)     
Increase at 6 months 2.1; -2.4 to 3.5 
(0.130 
0.8; -2.3 to 6.1 
(0.49) 
0.80 
(-3.5 to 4.0) 
Increase at 12months 1.1; -2.2 to 3.6 
(0.55) 
-0.3; -1.7 to 4.8 
(0.76) 
0.86 
(-3.1 to 5.3) 
IQR – inter-quartile range  
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Table 5.   Change in menstrual cycle characteristics from baseline to 6 and 12 months after 
treatment 
 
 
 Change at 6 months Change at 12 months 
 
 
mean (SD) 
( p-value; 95%CI) 
mean (SD) 
( p-value; 95%CI) 
Decrease in duration of 
menstrual flow ( days) 
1.4 (3.7)  
  
(p = 0.001; 0.6 to 2.2) 
 
1.7 (3.8)   
 
(p = 0.001); 0.8 to 2.6) 
Change in length of 
menstrual cycle (days) 
-0.3 (3.8)     
 
(p = 0.50; -1.2 to 0.6) 
0.7 (4.9) 
 
(p = 0.25; -0.5 to 1.9) 
 
 
 
 
 
